Meaxin (Imatinib)

Imatinib acts on tyrosine kinase‑driven pathways and is indicated for several oncologic conditions.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves hematologic and cytogenetic remission.
• Gastrointestinal stromal tumor (GIST): inhibits tumor growth and improves progression‑free survival in patients with KIT‑positive disease.
• Dermatofibrosarcoma protuberans (DFSP): induces tumor regression by targeting PDGFR signaling.

• Imatinib selectively inhibits the ATP‑binding sites of BCR‑ABL, c‑KIT, and PDGFR tyrosine kinases. By blocking these enzymes, it prevents downstream phosphorylation cascades that drive cellular proliferation, survival, and angiogenesis in malignant cells. The inhibition is competitive and reversible, leading to apoptosis of dependent cancer cells while sparing most normal tissues. The drug’s high affinity for the inactive conformation of these kinases enhances its potency across a range of mutant forms.

Imatinib may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Fatigue: generalized tiredness.
• Diarrhea: loose stools.
• Muscle cramps: involuntary tightening of skeletal muscles.
• Rash: mild skin eruption or itching.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Cardiac failure: reduced left‑ventricular ejection fraction.
• Severe neutropenia: marked decrease in white blood cells.
• Pulmonary hypertension: increased pressure in pulmonary arteries.

When prescribing Imatinib, clinicians should consider several safety precautions.

• Baseline assessment: obtain complete blood count, liver function tests, and renal function before initiating therapy.
• Monitoring: perform regular CBC and hepatic panel during treatment to detect cytopenias or liver injury.
• Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers that may alter plasma levels.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks; discuss with obstetric specialist.
• Cardiovascular risk: assess cardiac function in patients with pre‑existing heart disease.
• Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Imatinib interacts with several agents that can affect its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase imatinib exposure and toxicity.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations, compromising effectiveness.
• Antacids containing aluminum or magnesium: can decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Acid‑reducing agents (proton pump inhibitors, H2 blockers): may modestly lower imatinib levels; timing adjustment recommended.
• Warfarin: imatinib may enhance anticoagulant effect, requiring INR monitoring.
• Digoxin: possible increase in serum digoxin; monitor for toxicity.